Avalo Therapeutics (AVTX) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Market overview and disease landscape

• Hidradenitis suppurativa (HS) affects over 1% of the U.S. population, with significant underdiagnosis and long referral times, but increasing recognition is expected to grow the market rapidly.

• Aggregate sales for approved HS therapies are in the multiple billions of dollars and rising quickly.

AVTX-009 program and clinical rationale

• AVTX-009 is a high-affinity anti-IL-1β monoclonal antibody targeting a central inflammatory pathway in HS.

• IL-1β is upstream of TNF and IL-17, making it a strategic target for broader disease control.

• High affinity and specificity of AVTX-009 are expected to enhance lesion penetration and therapeutic effect.

Clinical trial design and endpoints

• The LOTUS phase II trial uses HiSCR75 as the primary endpoint, reflecting a more clinically meaningful response than HiSCR50.

• The trial will report a full spectrum of response data, including HiSCR50, HiSCR75, HiSCR90, and HiSCR100.

• Measures to control placebo response include experienced investigators, targeted site selection, and specialized training modules.